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123I neuroligands allow SPECT imaging of dopaminergic
and benzodiazepine systems in various movement disorders
including Parkinson’s disease, Huntington’s disease, pro-
gressive supranuclear palsy, multiple system atrophy, and
Wilson’s disease. Cocaine analogs with high affinity and
selectivity for dopamine transporter (DAT) sites in the
putamen and the caudate nucleus such as 123I-CIT [1], 123I-
altropane [2], and 123I-FPCIT [3] allow SPECT imaging of
the DAT system. Likewise, dopamine transporters can be
imaged with SPECT using 123I neuroligands such as
123IBZM [4], 123IBF [5], etc. Significant progress has been
made in the design of high-resolution SPECT cameras
dedicated for brain imaging. Also, improved physical
compensation and reconstruction algorithms have been
proposed, and some have been incorporated into commer-
cial software supplied by vendors to end-users. However, in
spite of the advances in algorithmic designs allowing
improved quantitative accuracy, absolute quantitation of
DAT or D2 has been and is still very challenging with
SPECT, unlike PET, due to the difficulty to accurately and
simply compensate for image-degrading factors such as
attenuation, scatter, limited spatial resolution, and low
sensitivity [6]. Sensitivity is an important impediment
against dynamic brain SPECT imaging which is required
to achieve absolute quantitation of the distributions of many
of these neuroligands. Photon attenuation and contributions
from scattered photons reduce the accuracy of measured
activities and activity concentrations. In addition, limited
spatial resolution causes a “hot” object that is less than two
to three times the system’s resolution in a “colder”
background to appear blurred with reduced activity con-
centration (partial volume effect). While the total recon-
structed counts within the object are conserved, the count
density is decreased from the true value because the data
are distributed over a larger area than the object’s true
activity distribution.
Advances in the quantification of dopaminergic neuro-
transmission studies using SPECT, especially for small
structures such as the putamen and caudate nucleus rely on
two improvements: (1) hardware improvements to enhance
spatial resolution and sensitivity and addition of compo-
nents or other imaging modalities (e.g., SPECT/MR [7]) to
allow anatomolecular fusion imaging and to enable correc-
tion for physical degrading factors and (2) software
improvements to achieve better image quality and achieve
more accurate quantification of physiological parameters.
In this issue of the European Journal of Nuclear Medicine
and Molecular Imaging, Crespo et al. [8] assess what level
of accuracy can be achieved when quantifying dopaminer-
gic 123I radioligands in Monte Carlo simulations of two
gamma cameras using different combinations of correction
techniques including system response function, scatter,
attenuation, and partial volume effect. This editorial gives
a summary of recent advances in brain SPECT instrumenta-
tion, compensation methods available for scatter, attenuation,
system response, partial volume effect, and motion. It also
explores the role and limitations of Monte Carlo simulation in
the development and performance assessment of quantitative
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protocols for brain SPECTand a critical appraisal of the future
of quantitative DAT imaging using brain SPECT in clinical
setting.
Due to the location of the striata deep within the brain,
the attenuation of photons emitted from DAT binding sites
is very substantial compared to cortical perfusion studies,
for example, and accounts for a reduction in signal of
approximately 75%. Attenuation correction, on the other
hand, is usually considered to be easy to achieve in the
brain except when accurate quantification is desired in all
regions [9]. It has been reported that modified uniform
attenuation maps that account for bone tissue yield accurate
attenuation compensation that is not significantly different
from nonuniform attenuation compensation [10]. Likewise,
scatter compensation can be achieved using spectral
approaches that rely on the estimation of scatter contribution
in one or several energy windows or more sophisticated
scatter compensation approaches such as those using neural
networks, spectral factor analyses, or statistical iterative
reconstruction techniques [11]. The absence of internal
organ motion in brain imaging simplifies greatly the motion
problem which can be tackled using head restraint and rigid
registration [12]. One of the major physical factors affecting
quantitation in DAT SPECT is partial volume effect due to the
combination of limited spatial resolution of the gamma
cameras available today (approximately 8 mm) and small size
of the caudate nucleus and putamen (similar size to spatial
resolution). This yields major underestimation of striatal
activity (e.g., [13, 14]) that requires to be compensated for
using some knowledge about the striatal volume from
another modality such as MRI. Under these conditions,
Crespo et al. [8] show that accurate quantitation of activity
concentration is feasible. However, quantitation of activity
concentration in the striatal volume is not synonymous to the
absolute quantitation of DAT population and the latter
requires kinetic modeling of the neuroligand density within
the nigrostriatal cellular space. While kinetic modeling is
feasible for many neuroligands used along with 123I (e.g.,
altropane [2]), the major difficulty resides in the collection of
short dynamic frames of the neurotransmitter study due to
the limited statistics associated with such studies. Further-
more, even in the presence of high-count statistics, the
mechanical motions involved and the bulk of the detector
heads limit the shortest time in which a complete set of
projections can be recorded to several minutes [15]. To
address this problem, several attempts have been made to
dramatically increase brain SPECT sensitivity using many
heads or ring-like geometry detectors that allow very fast
acquisition of a full set of projections. Although the use of
such systems is not widespread in clinical routine in brain
SPECT, they are of interest because they illustrate possible
future avenues of research. A good example of such systems
is the FASTSPECT developed at the University of Arizona
which consists of 24 position-sensitive NaI(Tl) detectors that
are completely stationary, along with a stationary set of 2-
mm pinhole collimators hence achieving high sensitivity
(fast dynamic brain scans) and high spatial resolution [16].
Another dedicated brain scanner with stationary annular NaI
(Tl) detector is the CERASPECT system developed by
Digital Scintigraphics Inc. [17], which is equipped with a
rotating collimator. A modified version of this collimator is
the SensOgrade, a variable focusing collimator which
samples the projections unequally with central regions more
heavily represented to compensate for attenuation from
central brain structures thus yielding a fourfold to ninefold
increase in sensitivity compared to conventional dual-head
cameras [18]. A third example is the SPRINT II system
developed at the University of Michigan which consists of
11 detectors arranged in a polygonal fashion and a rotating
collimator which allows the acquisition of a complete set of
fan-beam projection data within 1/12 of a rotation [19].
Another example of unconventional systems is the Neuro-
Focus™ multi-conebeam imager (Neurophysics Corporation,
Shirley, MA, USA), which produces tomographic SPECT
images with an intrinsic spatial resolution of approximately
3 mm. The operation of the NeuroFocus™ scanner follows
the same principles as scanning optical microscopes to obtain
high-resolution, three-dimensional images of biological tis-
sue. A highly focused point of light is scanned mechanically
in three dimensions to uniformly sample the volume under
observation. As an alternative to dynamic SPECT imaging
using multiple, fast rotations, strategies involving the use of
only a single, slow camera rotation have been proposed [20].
Further advances in electronics are permitting new counting
strategies, and advances in electronic component capability
are allowing for enhanced sensitivity [21].
Within the context of functional brain imaging, the aim
of quantification is to provide a reliable numerical measure
of brain function. It is always hypothesized that the
availability of accurate quantitative information about the
dopaminergic system would provide a higher diagnostic
accuracy than visual interpretation alone. Therefore, the
aim of the study by Crespo et al. [8] is to assess the
performance of various collimation geometries and image
correction strategies on the accuracy of semiquantitative
indices (specific uptake ratio) obtained from dopaminergic
neurotransmission SPECT studies with 123I-labeled radio-
ligands which might enable reliable standardization in
multicentric studies and the transfer of normal functional
brain databases.
Modeling and simulation of the SPECT image formation
process play a significant role in the development and
assessment of algorithms for quantitative brain imaging. In
particular, Monte Carlo techniques were extensively used to
analyze the performance of new collimators design for
planar imaging and SPECT [22]. Practical guidance could
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be offered for understanding trade-offs that must be
considered for clinical imaging. Selective comparisons
among different collimators could also be presented and
assessed quantitatively. Approaches to the collimator optimi-
zation problem and more sophisticated ‘task-dependent’
treatments and important considerations for collimators
design have been performed [22]. Well-established imaging
performance parameters of parallel-hole collimators could be
compared with those of fan- and cone-beam collimators
which have enjoyed considerable success in recent years,
particularly for brain SPECT. Monte Carlo simulations have
been shown to be very useful for the development,
validation, and comparative evaluation of image correction
and reconstruction techniques because it is possible to obtain
a reference image to which corrected/reconstructed images
should be compared [23]. Monte Carlo modeling thus allows
a detailed investigation of the spatial and energy distribution
of Compton scatter which would be difficult to perform
using the present experimental techniques, even with very
good energy resolution semiconductor detectors [11]. Monte
Carlo simulations are also powerful tools to investigate the
limits of algorithms developed for the correction of partial
volume effect by allowing to replicate realistic conditions in
emission tomography for a wide range of practical situations
and to study the effect of object shape and size on recovery
performance [24]. In addition, the assessment of the impact
of inherent assumptions such as accurate characterization of
system response function, perfect registration between MRI
and SPECT, anatomical image segmentation, and other
hypotheses regarding tracer distribution on quantification
bias is more straightforward compared to experimental
approaches [14].
Inverse Monte Carlo approaches with simultaneous com-
pensation for attenuation, scatter, and distance-dependent
collimator response have been advocated as a promising
alternative for SPECT reconstruction in the 1980s [25].
The interest in fully 3-D Monte Carlo-based statistical
reconstruction approaches spurred the development of
computationally efficient algorithms capable of obtaining
highly accurate quantitative data in clinically acceptable
computation times [26, 27] On the other hand, the capability
to theoretically model the propagation of photon noise
through SPECT reconstruction algorithms is fundamental in
evaluating both the quality and quantitative accuracy of
reconstructed images as a function of the parameters of the
algorithm. Monte Carlo methods can be used to check the
validity of the predictions of the theoretical formulations
through the computation of the sample statistical properties
of the algorithms under evaluation [28].
The combination of realistic computational anthropo-
morphic models of the human anatomy and accurate
models of the imaging process allows the simulation of
SPECT data that are ever closer to actual patient data [29].
Monte Carlo simulation techniques will find an increasingly
important role in the future of quantitative SPECT in the
light of the further development of realistic computational
models, the accurate modeling of projection data, and
computer hardware. However, caution must be taken to
avoid errors in the simulation process, and verification via
comparison with experimental and clinical data is crucial.
Advances in dedicated SPECT instrumentation stimulat-
ed the clinical use of high-resolution imaging of the brain
[6]. Recent studies seem to suggest that the time of clinical
application of quantitative brain SPECT imaging has come.
The technique was shown to provide a higher diagnostic
accuracy in differential diagnosis [30] and to improve
consistency in quantitative measurements between facilities
using different cameras and analysis software [31]. Quan-
titative brain SPECT incorporating advanced corrections for
attenuation, scatter, system response, and partial volume
will continue to play an important role both in clinical and
research settings [27, 32–34]. It is expected that the
development of more specific tracers in combination with
advances in neuroscience will expand the understanding of
the pathophysiology of neurological clinical diseases in the
coming years, hopefully leading to improved diagnosis and
treatment, and eventually to the implementation of preventive
techniques.
It is highly likely that automated operator-independent
analysis of high-resolution DAT SPECT images will lead to
largely reduced analysis variability, improved availability,
and increased diagnostic sensitivity, independent of observer
performance [35]. However, it should be emphasized that the
process of clinical diagnosis cannot be automated in a
straightforward manner. Despite the fact that automated
image analysis methods are essential, they should be
considered as complementary instruments to clinical diagno-
sis and decision-making process. Interpretation of functional
and molecular alterations observed in a SPECT scan requires
an enormous collection of understanding, involving physiol-
ogy, pathophysiology, and clinical science, which is difficult
to integrate in an easy to implement decision-making
algorithm or computer-aided diagnostic system.
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